Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

769 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.
Capodanno D, Baber U, Bhatt DL, Collet JP, Dangas G, Franchi F, Gibson CM, Gwon HC, Kastrati A, Kimura T, Lemos PA, Lopes RD, Mehran R, O'Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey RF, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. Capodanno D, et al. Among authors: rao sv. Nat Rev Cardiol. 2022 Dec;19(12):829-844. doi: 10.1038/s41569-022-00725-6. Epub 2022 Jun 13. Nat Rev Cardiol. 2022. PMID: 35697777 Review.
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.
Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA; Academic Bleeding Consensus Multidisciplinary Working Group. Rao SV, et al. Among authors: rao ak. Am Heart J. 2009 Dec;158(6):881-886.e1. doi: 10.1016/j.ahj.2009.10.008. Am Heart J. 2009. PMID: 19958852
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Leonardi S, et al. Among authors: rao sv. Am Heart J. 2010 Jul;160(1):65-72. doi: 10.1016/j.ahj.2010.04.008. Am Heart J. 2010. PMID: 20598974 Clinical Trial.
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
Steg PG, Mehta S, Jolly S, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Chrolavicius S, Rao SV, Granger CB, Pogue J, Laing S, Yusuf S. Steg PG, et al. Among authors: rao sv. Am Heart J. 2010 Dec;160(6):1029-34, 1034.e1. doi: 10.1016/j.ahj.2010.07.037. Am Heart J. 2010. PMID: 21146654 Clinical Trial.
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.
Chan MY, Sun JL, Wang TY, Lopes RD, Jolicoeur ME, Pieper KS, Rao SV, Newby LK, Mahaffey KW, Harrington RA, Peterson ED. Chan MY, et al. Among authors: rao sv. Am Heart J. 2010 Dec;160(6):1056-64, 1064.e2. doi: 10.1016/j.ahj.2010.09.001. Am Heart J. 2010. PMID: 21146658 Clinical Trial.
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Verheugt FW, et al. Among authors: rao sv. JACC Cardiovasc Interv. 2011 Feb;4(2):191-7. doi: 10.1016/j.jcin.2010.10.011. JACC Cardiovasc Interv. 2011. PMID: 21349458 Free article.
769 results